Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

@inproceedings{Ramaekers2016AbirateroneAF,
  title={Abiraterone Acetate for the Treatment of Chemotherapy-Na{\"i}ve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal},
  author={Bram L T Ramaekers and Rob Riemsma and F Tomini and Thea van Asselt and Sohan Deshpande and Steven Duffy and Nigel T Armstrong and Johan L. Severens and J. Kleijnen and Manuela M A Joore},
  booktitle={PharmacoEconomics},
  year={2016}
}
The National Institute for Health and Care Excellence (NICE) invited Janssen, the company manufacturing abiraterone acetate (AA; tradename Zytiga®), to submit evidence for the clinical and cost effectiveness of AA in combination with prednisone/prednisolone (AAP) compared with watchful waiting (i.e. best supportive care [BSC]) for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC). Kleijnen Systematic Reviews Ltd (KSR), in collaboration with Maastricht… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 11 references

Abiraterone and increased survival in metastatic prostate cancer.

The New England journal of medicine • 2011
View 6 Excerpts
Highly Influenced

National Institute for Health and Care Excellence.

European heart journal • 2015
View 1 Excerpt

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

Annals of oncology : official journal of the European Society for Medical Oncology • 2012
View 1 Excerpt

CYP17 inhibitors for prostate cancer therapy.

The Journal of steroid biochemistry and molecular biology • 2011
View 1 Excerpt

Similar Papers

Loading similar papers…